CXCR4-gp120-IIIB interactions induce caspase-mediated apoptosis of prostate cancer cells and inhibit tumor growth

被引:10
作者
Singh, Shailesh [1 ]
Bond, Vincent C. [2 ]
Powel, Michael [2 ]
Singh, Udai P. [3 ]
Bumpers, Harvey L. [2 ]
Grizzle, William E. [4 ]
Lillard, James W., Jr. [1 ,2 ]
机构
[1] Univ Louisville, Sch Med, James Graham Brown Canc Ctr, Dept Microbiol & Immunol, Louisville, KY 40202 USA
[2] Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA
[3] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC USA
[4] Univ Alabama Birmingham, Ctr Comprehens Canc, Dept Pathol, Birmingham, AL 35294 USA
关键词
LUNG-CANCER; ANGIOGENESIS; CARCINOMA; EXPRESSION; RECEPTOR; CXCR4; METASTASIS; PROMOTES; MATRIX-METALLOPROTEINASE-9; GLYCOPROTEIN;
D O I
10.1158/1535-7163.MCT-08-0643
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CXC chemokine receptor 4 (CXCR4) has been implicated in prostate cancer metastasis and this receptor also acts as a coreceptor for HIV-1 120-kDa glycoprotein variant 11113 (gp120-IIIB). The interaction between CXCR4 and gp120-IIIB has been shown to mediate apoptosis of both immune and endothelial cells. In this study, we have examined the effects of gp120-IIIB on hormone-refractory prostate cancer cells (PC3 and DU145) in vitro and tumor growth in vivo. Normal prostatic epithelial (PrEC) and prostate cancer cell lines were treated with gp120-IIIB with or without anti-CXCR4 antibody. Caspase expression was evaluated by real-time PCR and active caspase assays. Apoptosis was determined by flow cytometry. gp120-IIIB treatment correlated with active caspase-3 and -9 expression and apoptosis of prostate cancer cells but not PrEC cells. This effect was significantly inhibited after CXCR4 blockade. PC3 and DU145 tumor-bearing mice received intraperitoneal injections of gp120-IIIB and controls received bovine serum albumin in PBS. PC3 and DU145 tumor sizes were measured over time and excised tumors were evaluated for CD44, CD34, lymphatic endothelial cell marker LYVE-1, active caspase-3, and active caspase-9 expression by immunohistochemistry. The tumor size in mice receiving gp120-IIIB was significantly smaller than compared with tumors in control mice. This regression was associated with significant decreases in CD44, CD34, and LYVE-1 and increases in active caspase-3 and -9 expression. These results suggest that gp120-IIIB induced apoptosis in prostate cancer cells and reduced tumor-associated lymphoendothelial cells. [Mol Cancer Ther 2009;8(1):178 - 84]
引用
收藏
页码:178 / 184
页数:7
相关论文
共 47 条
[1]  
Arya Manit, 2004, J Exp Ther Oncol, V4, P291
[2]   LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan [J].
Banerji, S ;
Ni, J ;
Wang, SX ;
Clasper, S ;
Su, J ;
Tammi, R ;
Jones, M ;
Jackson, DG .
JOURNAL OF CELL BIOLOGY, 1999, 144 (04) :789-801
[3]   Assessment of the vascularization in prostatic carcinoma: A morphometric investigation [J].
Barth, PJ ;
Weingartner, K ;
Kohler, HH ;
Bittinger, A .
HUMAN PATHOLOGY, 1996, 27 (12) :1306-1310
[4]   CXCR4 and CD4 mediate a rapid CD95-independent cell death in CD4+ T cells [J].
Berndt, C ;
Möpps, B ;
Angermüller, S ;
Gierschik, P ;
Krammer, PH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (21) :12556-12561
[5]   CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy [J].
Bettencourt, MC ;
Bauer, JJ ;
Sesterhenn, IA ;
Connelly, RR ;
Moul, JW .
JOURNAL OF UROLOGY, 1998, 160 (02) :459-465
[6]   Synthesis of procaspases-3 and-7 during apoptosis in prostate cancer cells [J].
Bowen, C ;
Voeller, HJ ;
Kikly, K ;
Gelmann, EP .
CELL DEATH AND DIFFERENTIATION, 1999, 6 (05) :394-401
[7]  
BRAWER MK, 1994, CANCER, V73, P678, DOI 10.1002/1097-0142(19940201)73:3<678::AID-CNCR2820730329>3.0.CO
[8]  
2-6
[9]  
Bredeek UF, 2007, EUR J MED RES, V12, P427
[10]   AMD3100 plus G-CSF can successfully mobilize CD34+cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data [J].
Calandra, G. ;
McCarty, J. ;
McGuirk, J. ;
Tricot, G. ;
Crocker, S-A ;
Badel, K. ;
Grove, B. ;
Dye, A. ;
Bridger, G. .
BONE MARROW TRANSPLANTATION, 2008, 41 (04) :331-338